Dossier assessment
Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Report documents
-
Dossier assessment
Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Project details
- Project no.
- G15-05
- Commission
- Commission awarded on 01.06.2015 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with § 35a (para. 1, sentence 10) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Olaparib report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
Connected Projects
-
Dossier assessment
Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (maintenance in combination with durvalumab; endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Olaparib (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed